Zepzelca\u00ae (lurbinectedin) and Atezolizumab (Tecentriq\u00ae) Combination Granted U.S. FDA Priority Review for First-Line Ma

  • Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m.